Regkirona gets temporary approval from Switzerland

Regkirona, Korea's first Covid-19 treatment, won two-year temporary use authorization from regulators in Switzerland, developer Celltrion said Friday.

Celltrion’s Regkirona, the first homegrown Covid-19 treatment [CELLTRION]

Regkirona, Korea’s first Covid-19 treatment, won two-year temporary use authorization from regulators in Switzerland, developer Celltrion said Friday.

It is approved for adults with coronavirus who do not require supplemental oxygen or hospitalization and who are at high risk of developing severe symptoms.

So far, Regkirona has won marketing approvals from Korea’s Ministry of Food and Drug Safety and the European Commission. Brazil and Indonesia issued emergency-use authorizations, while Peru and Australia granted conditional use approvals.

Celltrion believes Regkirona will contribute in preventing the spread of the virus in Switzerland, which has seen a growing number of infections.

According to data from Worldometer, the number of Covid-19 cases in Switzerland totaled 1.6 million as of Jan. 12, with 12,529 deaths. Daily Covid-19 cases rose to the 15,000-level.

BY SARAH CHEA [chea.sarah@joongang.co.kr]